A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer

Recruiting Phase 1 Interventional Study
Breast Cancer Hormone-receptor-positive Breast Cancer HER2-negative Breast Cancer HR-positive Breast Cancer HR+/HER2- Breast Cancer Locally Advanced Breast Cancer Metastatic Breast Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
242 (estimated)
Sponsor
Prelude Therapeutics Incorporated · Industry
Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
This first-in-human, open-label, multicenter study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of PRT13722, an oral KAT6A protein degrader, in adults with locally advanced or metastatic Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. PRT13722 will be evaluated as monotherapy a…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures. * histological or cytological diagnosis of locally advanced or metastatic HR-positive/HER2-negat…
Contacts

Study Contact (Please Do Not Disclose Personal Information)

See Email

clinicaltrials@preludetx.com

CONTACT